Physician profile
Pradip Rustagi
NPI 1881709699
$8,297.57
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,633 · 2020: $1,400 · 2021: $2,183 · 2022: $1,745 · 2023: $217 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $804.07 | 2019-2022 | |
| Seagen INC. | $704.54 | 2019-2022 | |
| Genzyme Corporation | $551.09 | 2019-2022 | |
| Celgene Corporation | $472.21 | 2019-2024 | Opdualag, Pomalyst |
| Amgen INC. | $460.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $362.76 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $348.99 | 2019-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $319.77 | 2019-2022 | |
| Pfizer INC. | $317.92 | 2019-2022 | |
| Exelixis INC. | $309.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $271.68 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $270.22 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $265.32 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $231.64 | 2019-2021 | |
| Tesaro, INC. | $204.77 | 2019 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradip Rustagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.